Clinical Trials
32
Active:0
Completed:5
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:16
Phase 2:5
+3 more phases
Drug Approvals
9
PHILIPPINES:9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (31 trials with phase data)• Click on a phase to view related trials
Phase 1
16 (51.6%)Phase 2
5 (16.1%)Phase 3
4 (12.9%)Not Applicable
3 (9.7%)Phase 4
2 (6.5%)Early Phase 1
1 (3.2%)A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Not Applicable
Not yet recruiting
- Conditions
- First-line Advanced NSCLC Patients
- Interventions
- Drug: PD-1 Inhibitor + ChemotherapyDrug: Carboplatin/Paclitaxel
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 240
- Registration Number
- NCT07171606
- Locations
- 🇨🇳
Institute of The Shanghai Pulmonary Hospital, Shanghai, China
Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects
Not Applicable
Not yet recruiting
- Conditions
- Safety Issues
- Interventions
- Drug: SSS55
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 26
- Registration Number
- NCT07058779
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 48
- Registration Number
- NCT07057726
- Locations
- 🇨🇳
SSS39, Beijing, China
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: SPGL008
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 96
- Registration Number
- NCT07038005
A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-06-23
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 30
- Registration Number
- NCT07032298
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found